目前,免疫联合化疗已经成为广泛期小细胞肺癌(extensive-stage small cell lung cancer,ES-SCLC)的一线治疗标准方案.近年来,免疫检查点抑制剂(immune checkpoint inhibitors,ICIs)在肺癌领域受到了广泛的关注和研究.同时,在此过程中也伴随着诸多挑战与考验,如生物标志物的探索、新靶点新模式的探讨和特殊人群管理等.本文综述了ES-SCLC免疫治疗领域的研究进展,并据此展望该领域的未来发展趋势与潜在方向.
Abstract
At present,immunotherapy combined with chemotherapy has become the first-line standard of treat-ment for extensive-stage small cell lung cancer(ES-SCLC).In recent years,immune checkpoint inhibitors(ICIs)have received extensive attention and research in the field of lung cancer.At the same time,there are many challenges and tests in this process,such as the exploration of biomarkers,the exploration of new targets and new models,and the management of special popula-tions.This article reviews the research progress in the field of ES-SCLC immunotherapy,and looks forward to the future devel-opment trend and potential direction of this field.
维普
万方数据